急性脑损伤住院成人抗癫痫药物预防的真实世界模式与结局
该研究分析美国1400余家医院的PINC AI医疗数据库,纳入739213例成人急性脑损伤患者(缺血性卒中568254例、出血性卒中86842例、创伤性脑损伤84117例),排除癫痫或惊厥患者。预防性使用左乙拉西坦或苯妥英的队列在缺血性卒中占2%、出血性卒中占37%、创伤性脑损伤占46%。调整疾病严重度后,预防与缺血性卒中死亡率升高相关(HR 2.02,95%CI 1.89-2.16),与出血性卒中死亡率降低相关(HR 0.83,95%CI 0.79-0.87),与创伤性脑损伤死亡率无显著关联(HR 0.97,95%CI 0.89-1.06);各型均与回家出院率降低相关。作者假设神经严重度和危重程度是主要驱动因素,但抗癫痫药物与结局的独立关联需进一步研究。
要点
- 缺血性卒中预防性用药比例仅2%,出血性卒中37%,创伤性脑损伤46%,出血性和创伤性脑损伤预防更常见。
- 预防用药组更常接受机械通气、开颅/去骨瓣减压、血管升压药和麻醉药,提示病情更重。
- 调整严重度后,预防与缺血性卒中死亡率升高相关(HR 2.02,95%CI 1.89-2.16),与出血性卒中死亡率降低相关(HR 0.83,95%CI 0.79-0.87)。
- 创伤性脑损伤中预防与死亡率无显著关联(HR 0.97,95%CI 0.89-1.06)。
- 各型急性脑损伤中,预防均与回家出院率降低相关(缺血性卒中HR 0.40,出血性卒中HR 0.61,创伤性脑损伤HR 0.69)。
适用人群与场景
- 年龄≥18岁、因急性脑损伤(缺血性卒中、出血性卒中或创伤性脑损伤的国际疾病分类编码)入院且住院至少2天的成人患者。
- 排除潜在已使用抗癫痫药物者和癫痫/惊厥患者。
- 数据来自美国1400余家医院,索引日期为入院第2天。
诊断标准与关键阈值
- 预防队列定义:索引日期接受左乙拉西坦或苯妥英;对照队列:索引日期未接受任何抗癫痫药物。
研究设计与关键结果
- 研究类型为基于PINC AI医疗数据库的分析,纳入739213例成人急性脑损伤患者:缺血性卒中568254例、出血性卒中86842例、创伤性脑损伤84117例。
- 预防性用药比例:缺血性卒中10959/568254(2%),出血性卒中31970/86842(37%),创伤性脑损伤38331/84117(46%)。
- 预防组更常接受机械通气、开颅/去骨瓣减压、血管升压药和麻醉药。
- 调整疾病严重度标志后,预防与死亡率关联:缺血性卒中HR 2.02(95%CI 1.89-2.16);出血性卒中HR 0.83(95%CI 0.79-0.87);创伤性脑损伤HR 0.97(95%CI 0.89-1.06)。
- 预防与回家出院率降低相关:缺血性卒中HR 0.40(95%CI 0.37-0.42);出血性卒中HR 0.61(95%CI 0.58-0.64);创伤性脑损伤HR 0.69(95%CI 0.68-0.72)。
- 在所有急性脑损伤中,机械通气与结局呈强关联。
证据类型、等级与局限
- 证据类型:基于大型医疗数据库的分析。
- 作者假设神经严重度和危重程度是结局的主要驱动因素。
- 局限:抗癫痫药物与结局的独立关联需进一步研究。
对床旁实践的改变
- 作者认为,神经严重度和危重程度可能是结局的主要驱动因素,抗癫痫药物与结局的独立关联需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There is low-quality evidence for antiseizure medication (ASM) prophylaxis in acute brain injuries. We examined ASM prophylaxis patterns and explored the association with hospital outcomes in acute brain injury.
METHODS: We analyzed the PINC AI Healthcare Database with data from more than 1,400 US hospitals. We included adults aged ≥ 18 years admitted for at least 2 days with acute brain injury (International Classification of Diseases codes for ischemic stroke [IS], hemorrhagic stroke [HS], and traumatic brain injury [TBI]) and excluded potential prevalent users and patients with epilepsy/seizures. Index date was the second day of admission. The ASM prophylaxis cohort received levetiracetam or phenytoin on the index date; the control cohort did not receive any ASM on the index date. Outcomes were time-to-mortality and time-to-home discharge.
RESULTS: In total, 739,213 patients were eligible: 568,254 with IS, 86,842 with HS, and 84,117 with TBI. ASM prophylaxis was prescribed in 10,959/568,254 (2%) patients with IS, 31,970/86,842 (37%) patients with HS, and 38,331/84,117 (46%) patients with TBI. Patients on prophylaxis more frequently received mechanical ventilation, craniectomies/craniotomies, vasopressors, and anesthetics. After adjusting for markers of illness severity, prophylaxis was associated with mortality (IS: hazard ratio [HR] 2.02, 95% confidence interval [CI] 1.89-2.16; HS: HR 0.83; 95% CI 0.79-0.87; TBI: HR 0.97, 95% CI 0.89-1.06). Prophylaxis was associated with lower home discharge (IS: HR 0.40, 95% CI 0.37-0.42; HS: HR 0.61, 95% CI 0.58-0.64; TBI: HR 0.69, 95% CI 0.68-0.72). Across all acute brain injuries, mechanical ventilation exhibited strong association with outcomes.
CONCLUSIONS: Antiseizure medication prophylaxis was higher in TBI and HS compared with IS. Markers of illness severity (e.g., mechanical ventilation, neurosurgical procedures) were associated with more frequent prophylaxis. Prophylaxis exhibited differential associations with mortality (higher in IS, lower in HS and TBI). Prophylaxis was associated with lower home discharge across all acute brain injuries. We hypothesize that neurologic severity and critical illness severity are primary drivers of outcomes. However, the independent association of ASMs with outcomes warrants further investigation.
参考来源
- Cheng D, Fernandes MB, Westover MB, et al. Real-World Antiseizure Medication Prophylaxis and Outcomes in Hospitalized Adults with Acute Brain Injuries. Neurocrit Care. 2025. PMID: 41034682. doi:10.1007/s12028-025-02345-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。